Differences in Medication Adherence, Satisfaction and Clinical Symptoms in Schizophrenic ‎Outpatients Taking Different Antipsychotic Regimens

Manal Ihbeasheh's picture
Journal Title, Volume, Page: 
current drug safety . 2011 Nov 1;6(5):285-90.
Year of Publication: 
2011
Authors: 
Manal S. Ihbesheh
Department of Biochemistry, College of Pharmacy, An-Najah National University, Nablus, Palestine
Current Affiliation: 
Faculty of Medicine & Health Sciences, Department of Biomedical Sciences, An-Najah National University, Nablus, Palestine
Waleed M. Sweileh
Department of Pharmacology and Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine
Ikhlas S. Jarar
Department of Pharmacology and Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine
Ansam F. Sawalha
Department of Pharmacology and Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine
Adham S. Abu Taha
Department of Pharmacology and Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine
Sa'ed H. Zyoud
WHO Collaborating Centre for Drug Information, National Poison Centre, Universiti Sains Malaysia (USM), Penang, Malaysia
Donald E. Moriskyd
Department of Community Health Sciences UCLA School of Public Health, Los Angeles, CA, USA
Preferred Abstract (Original): 
Abstract: Objective: To investigate differences in medication adherence, treatment satisfaction and clinical symptoms in schizophrenic outpatients taking different antipsychotic treatment regimens. Methodology: Medication adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS-8) while treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were measured using the 24-item expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and analyzed using SPSS 16 for windows. Results: A convenience sample of 131 schizophrenic patients was studied. Patients belonged to 7 groups based on their antipsychotic treatment regimens. There was no significant difference in the means of adherence (P=0.6) and BPRS domains: positive (P=0.6), negative (P=0.8), manic (P=0.2) and depression (P=0.9) scores among the studied groups. Satisfaction with side effect domain was significantly different among studied groups (P=0.006, F=3). However, no significant difference was found in other satisfaction domains: effectiveness (P=0.8), convenience (P=0.3), and global satisfaction (P=0.8). Conclusions: Medications adherence, most treatment satisfaction domains and clinical symptom scores were not significantly different among patients taking different antipsychotic regimens.